Interferon β in multiple sclerosis;Interferón β en la esclerosis múltiple

Revista de Neurologia

Volumn 36, Issue 10, 2003, Pages 980-990

  Prieto, J M ^a   Lema, M ^a  

^a Instituto de Salud Carlos III   (Spain)

Author keywords

Interferon; Multiple sclerosis

Indexed keywords

BETA1A INTERFERON; INTERFERON BETA SERINE; ANTIVIRUS AGENT; BETA INTERFERON;

CLINICAL TRIAL; COMPARATIVE STUDY; DISEASE COURSE; DOSE RESPONSE; DRUG MECHANISM; DRUG TOLERABILITY; EUROPE; HUMAN; LONG TERM CARE; MULTIPLE SCLEROSIS; REVIEW; SIDE EFFECT; SKIN DISEASE; UNITED STATES; CONTROLLED CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL;

ANTIVIRAL AGENTS; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; INTERFERON-BETA; MULTIPLE SCLEROSIS; RANDOMIZED CONTROLLED TRIALS;

EID: 0038650684     PISSN: 02100010     EISSN: None     Source Type: Journal    
DOI: 10.33588/rn.3610.2003032     Document Type: Review

References (73)

1. Goodkin DE. Interferon beta treatment for multiple sclerosis: persisting questions. Multiple Sclerosis 1996; 1: 321-4.
2. McDonald WI, Compston A, Edan G, Goodkin D, Hartung HP, Lublin FD, et al. Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the Diagnosis of Multiple Sclerosis. Ann Neurol 2001; 50: 121-7.
3. Thompson AJ, Montalbán X, Barkhoff F, Brochet B, Filippi M, Miller DH, et al. Diagnostic criteria for primary progressive multiple sclerosis: a position paper. Ann Neurol 2000; 47: 831-5.
4. Prieto JM. Contribución de la resonancia magnética al estudio de la esclerosis múltiple. Tesis Doctoral. Universidad de Santiago de Compostela. Santiago de Compostela; 1987.
5. Prieto JM, Lema M, López-Ibor L, De Toro FJ, Castillo J, Noya M. La resonancia magnética en el estudio de la esclerosis múltiple: correlaciones clínicas y comparación con otros estudios complementarios. Rev Esp Neurol 1989; 4: 627-34.
6. Filippi M, Rovaris M, Rice GP, Sormani MP, Iannucci G, Giacomotti L, et al. The effect of cladribine on T(1) 'black hole' changes in progressive MS. J Neurol Sci 2000; 176: 42-4.
7. Filippi M, Rovaris M, Iannucci G, Mennea S, Sormani MP, Comi G. Whole brain volume changes in patients with progressive MS treated with cladribine. Neurology 2000; 55: 1714-8.
8. Hafler DA, Weiner HL. MS: a CNS systemic autoimmune disease. Immunol Today 1989; 10: 104-7.
9. Wucherpfennig KW. Autoimmunity in the central nervous system: mechanisms of antigen presentation and recognition. Clin Immunol Immunopathol 1994; 72: 293-306.
10. Hauser SL, Bhan AK, Gilles F, Kemp M, Kerr C, Weiner HL. Immunohistochemical analysis of the cellular infiltrate in multiple sclerosis lesions. Ann Neurol 1986; 19: 578-87.
11. Lucchinetti CF, Brück W, Rodríguez M, Lassmann H. Distinct patterns of multiple sclerosis pathology indicates heterogeneity in pathogenesis. Brain Pathol 1996; 6: 259-74.
12. Trapp BD, Peterson J, Ransohoff RM, Rudick R, Mörk S, Bö L. Axonal transection in the lesions of multiple sclerosis. N Engl J Med 1998; 338: 278-85.
13. Leppert D, Ford J, Stabler G, Grygar C, Lienert C, Huber S, et al. Matrix metalloproteinase-9 (gelatinase B) is selectively elevated in CSF during relapses and stable phases of multiple sclerosis. Brain 1998; 121: 2327-34.
14. Rodríguez M, Wynn DR, Kimlinger TK, Katzmann JA. Terminal component of complement (C9) in the cerebrospinal fluid of patients with multiple sclerosis and neurologic controls. Neurology 1990; 40: 855-7.
15. + current expression in cultured oligodendrocytes. J Membr Biol 1991; 124: 127-37.
16. Giovannoni G, Hartung HP. The immunopathogenesis of multiple sclerosis and Guillain-Barré syndrome. Curr Opin Neurol 1996; 9: 165-77.
17. Hartung HP. Pathogenesis of inflammatory demyelination: implications for therapy. Curr Opin Neurol 1995; 8: 191-9.
18. Traugott U. Evidence for immunopathogenesis. In SD Cook, ed. Handbook of multiple sclerosis. 3 ed. Nueva York: Marcel Dekker, Inc; 2001. p. 163-92.
19. Andersson PB, Waubant E, Goodkin D. How should we proceed with disease-modifying treatments for multiple sclerosis? Lancet 1997; 349: 586-7.
20. Compston A. Treatment and management of multiple sclerosis. In Compston A, Ebers G, Lassman H, McDonald I, Mattews B, Wekerle H, eds. McAlpine's multiple sclerosis. 3 ed. Londres: Churchill Livingstone; 1998. p. 437-97.
21. Isaacs A, Lindenmann J. Virus interference I: the interferon. Proc R Soc Lond 1957; 147: 258-67.
22. Jacobs L, O'Malley J, Freeman A, Ekes R. Intrathecal interferon reduces exacerbations of multiple sclerosis. Science 1981; 214: 1026-8.
23. Jacobs L, Salazar AM, Herndon R, Reese PA, Freeman A, Josefowicz R, et al. Multi-centre double-blind study of effect of intrathecally administered natural human fibroblast interferon on exacerbations of multiple sclerosis. Lancet 1986; 2: 1411-3.
24. Panitch HS, Hirsch RL, Haley AS, Johnson KP. Exacerbations of multiple sclerosis in patients treated with gamma interferon. Lancet 1987; 1: 893-5.
25. Panitch HS, Hirsch RL, Schindler J, Johnson KP. Treatment of multiple sclerosis with gamma interferon: exacerbations associated with activation of the immune system. Neurology 1987; 37: 1097-102.
26. Karp CL, van Boxel-Dezaire AHH, Byrnes AA, Nagelkerten L. Interferon-β in multiple sclerosis: altering the balance of interleukin-12 and interleukin-10? Curr Opin Neurol 2001; 14: 361-8.
27. Yong VW, Chabot S, Stuve O, Williams G. Interferon beta in the treatment of multiple sclerosis. Mechanisms of action. Neurology 1998; 51: 682-9.
28. Paty DW, Li DKB, UBC MS/MRI Study Group IFN-β Multiple Sclerosis Study Group. Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. II. MRI analysis results of a multicenter, randomized, double-blind, placebo-controlled trial. Neurology 1993; 43: 662-7.
29. Calabresi PA, Tranquill LR, Dambrosia JM, Stone LA, Maloni H, Bash CN, et al. Increases in soluble VCAM-1 correlate with a decrease in MRI lesions in multiple sclerosis treated with interferon β-1b. Ann Neurol 1997; 41: 669-74.
30. Dhib-Jalbut S, Jiang H, Williams GJ. The effect of interferon β-1b on lymphocyte-endothelial cell adhesion. J Neuroimmunol 1996; 71: 215-22.
31. Berman JW, Guida MP, Warren J, Amat J, Brosnan CF. Localization of monocyte chemoattractant peptide-1 expression in the central nervous system in experimental autoimmune encephalomyelitis and trauma in the rat. J Immunol 1995; 156: 3017-23.
32. Stuve O, Dooley NP, Uhm JH, Antel JP, Francis GS, Williams G, et al. Interferon β-1b decreases the migration of T Lymphocytes in vitro: effects on matrix metalloproteinase-9. Ann Neurol 1996; 40: 853-63.
33. Leppert D, Waubant E, Burk MR, Oksenberg JR, Hauser SL. Interferon beta-1b inhibits gelatinase secretion and in vivo migration of human T cells: a possible mechanism for treatment efficacy in multiple sclerosis. Ann Neurol 1996; 40: 846-53.
34. Stuve O, Chabot S, Jung SS, Williams G, Yong VW. Chemokine-enhanced migration of T lymphocytes is antagonized by interferon beta1b through an effect on matrix-metalloproteinase-9. J Neuroimmunol 1997; 80: 38-46.
35. Rudick RA, Ransohoff RM, Lee JC, Peppler R, Yu M, Mathisen PM, et al. In vivo effects of interferon beta-1 a on immunosuppressive cytokines in multiple sclerosis. Neurology 1998; 50: 1294-3000.
36. Cebrián E. Estudio de interleucinas en esclerosis múltiple. Tesis doctoral. Universidad de Santiago de Compostela. Santiago de Compostela; 2001.
37. Rudick RA, Cookfair D, Ransohoff RM, Jacobs L, Hemdon R, Richert J, et al. CSF abnormalities in a phase III trial of Avonex (IFN-1a) for relapsing multiple sclerosis. Ann Neurol 1996; 40: 516.
38. Van Boxel-Dezaire AH, van Trigt-Hoff SC, Killestein J, Schrijver HM, Van Houwelingen JC, Polman CH, et al. Contrasting responses to interferon beta-1b treatment in relapsing-remitting multiple sclerosis: does baseline interleukin-12p35 messenger RNA predict the efficacy of treatment? Ann Neurol 2000; 48: 313-22.
39. Hohlfeld R, Wiendl H. The ups and downs of multiple sclerosis therapeutics. Ann Neurol 2001; 49: 281-4.
40. Knobler RI, Greenstein JI, Johnson KP, Lublin FD, Panitch HS, Conway K, et al. Systemic recombinant human interferon-beta treatment of relapsing-remitting multiple sclerosis: pilot study analysis and sixyear follow-up. J Interferon Res 1993; 13: 333-40.
41. The IFNB Multiple Sclerosis Study Group. Interferon beta-1b is effective in relapsing-remitting multiple sclerosis: I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. Neurology 1993; 43: 655-61.
42. Paty DW, Li DKB, UBC/MRI Study Group, IFNB Multiple Sclerosis Study Group. Interferon beta-1b is effective in remitting and relapsing multiple sclerosis: II. MRI analysis results of a multicenter, randomized, double-blind, placebo-controlled trial. Neurology 1993; 43: 662-7.
43. IFNB Multiple Sclerosis Study Group and the University of British Columbia MS/MRI Analysis Group. Interferon beta-1b in the treatment of multiple sclerosis: final outcome of the randomized controlled trial. Neurology 1995; 45: 1277-85.
44. Jacobs L, Salazar AM, Hemdon R, Reese PA, Freeman A, Jozefowicz R, et al. Intratechally administered natural human fibroblast interferon reduces exacerbations of multiple sclerosis: results of a multicentre double-blind study. Arch Neurol 1987; 44: 589-95.
45. Jacobs LD, Cookfair DL, Rudick RA, Herndon RM, Richert JR, Salazar AM, et al. Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. Ann Neurol 1996; 39: 285-94.
46. Rudick RA, Fisher E, Lee JC, Simon J, Jacobs L, the Multiple Sclerosis Collaborative Research Group. Use of brain parenchymal fraction to measure whole brain atrophy in relapsing-remitting MS. Neurology 1999; 53: 1698-704.
47. PRISMS Study Group. Randomized double-blind, placebo-controlled study of interferon-beta-1a in relapsing/remitting multiple sclerosis. Lancet 1998; 352: 1498-504.
48. Fernández O, Antigüedad A, Arbizu T, Capdevila A, de Castro P, Correa de Sa JC, et al. Treatment of relapsing-remitting multiple sclerosis with natural interferon beta: a multicenter, randomized clinical trial. Mult Scler 1995; 1: 67-9.
49. The PRISMS Study Group and the University of British Columbia MS/MRI Analysis Group. PRISMS-4: long-term efficacy of interferon-β-la in relapsing MS. Neurology 2001; 56: 1628-36.
50. Freedman MS, Once-Weekly Interferon for MS (OWIMS) Study Group. Dose-dependent clinical and magnetic resonance imaging efficacy of Interferon beta-1a (Rebif®) in multiple sclerosis. Ann Neurol 1998; 44: 992.
51. Durelli L, Verdun E, Barbero P, Bergui M, Versino E, The Independent Comparison of Interferon (INCOMIN) Trial Study Group, et al. Every-other-day interferon beta-1b versus once-weekly interferon beta-1a for multiple sclerosis: results of a 2-year prospective randomised multicentre study (INCOMIN). Lancet 2002; 359: 1453-60.
52. Panitch H, Goodin DS, Francis G, Chang P, Coyle PK, O'Connor P, et al, for the EVIDENCE (Evidence of Interferon Dose-response: European North American Comparative Efficacy) Study Group and the University of British Columbia MS/MRI Research Group. Randomized, comparative study of interferon beta-1a treatment regimens in MS: the EVIDENCE trial. Neurology 2002; 59: 1496-506.
53. th Annual Meeting. Denver, CO: American Academy of Neurology; 2002.
54. Clanet M, Radue EW, Kappos L, Hartung HP, Hohlfeld R, The European Interferon Beta-1a (Avonex) Dose-Comparison Study Investigators, et al. A randomized, double-blind, dose-comparison study of weekly interferon β-1a in relapsing MS. Neurology 2002; 1507-17.
55. th Annual Meeting. Denver, Co: American Academy of Neurology; 2002.
56. European Study Group on Interferon β-1b in Secondary Progressive MS. Placebo-controlled multicentre randomised trial of Interferon β-1b in treatment of secondary progressive multiple sclerosis. Lancet 1998; 352: 1491-7.
57. Kappos L, Polman C, Pozzilli C, Thompson A, Beckmann K, The European Study Group in Interferon β-1b in Secondary Progressive MS, et al. Final analysis of the European multicenter trial on IFNβ-1b in secondary-progressive MS. Neurology 2001; 57: 1969-75.
58. nd Annual Meeting. San Diego, CA: American Academy of Neurology; 2000.
59. SPECTRIMS Study Group. Randomized controlled trial of interferonbeta-1a in secondary progressive MS: clinical results. Neurology 2001; 56: 1496-504.
60. Li DKB, Zhao GJ, Paty DW. Randomized controlled trial of interferon-beta-1a in secondary progressive MS: MRI results. Neurology 2001; 56: 1505-13.
61. Cohen JA, Cutter GR, Fischer JS, Goodman AD, Heidenreich FR, The IMPACT Study Group, et al. Benefit of interferon β-1a on MSFC progression in secondary progressive MS. Neurology 2002; 59: 679-87.
62. Comi G. Why treat early multiple sclerosis patients? Curr Opin Neurol 2000; 13: 235-40.
63. Schwid SR, Bever CT. The cost of delaying treatment in multiple sclerosis. What is lost is not regained. Neurology 2001; 56: 1620.
64. Jacobs LD, Beck RW, Simon JH, Kinkel RP, Brownscheidle, The CHAMPS Study Group, et al. Intramuscular Interferon beta-1a therapy initiated during a first demyelinating event in multiple sclerosis. N Engl J Med 2000; 343: 898-904.
65. Comi G, Filippi M, Barkhof F, Durelli L, Edan G, Fernández O, et al. Effect of early treatment interferon treatment on conversion to definite multiple sclerosis: a randomised study. Lancet 2001; 357: 1576-82.
66. Álvarez-Cermeño JC. Lesión axonal inicial en la esclerosis múltiple. Razones para un tratamiento precoz. Rev Neurol 2002; 35: 221-7.
67. Alam J, Goelz S, Rioux P, Scaramucci J, Jones W, McAllister A, et al. Comparative pharmacokinetics and pharmacodynamics of two recombinant human interferon beta-1a (IFN beta-1a) products administered intramuscularly in healthy male and female volunteers. Pharm Res 1997; 14: 546-9.
68. Abdul-Ahad AK, Galazka AR, Revel M, Biffoni M, Borden EC. Incidence of antibodies to interferon-beta in patients treated with recombinant human interferon-beta 1a from mammalian cells. Cytokines Cell Mol Ther 1997; 3: 27-32.
69. Antonelli G, Bagnato F, Pozzilli C, Simeoni E, Bastianelli S, Currenti M, et al. Development of neutralizing antibodies in patients with relapsing-remitting multiple sclerosis treated with IFN-beta1a. J Interferon Cytokine Res 1998; 18: 345-50.
70. Río J, Barbera N, Tintoré M, Brieva L, Montalbán X. Anticuerpos neutralizantes en pacientes con esclerosis múltiple tratados con IFN beta-1b. Med Clin 2000; 12; 169-70.
71. Guidelines for physicians with patients on IFN-1b: the use of an assay for neutralizing antibody. Neurology 1996; 47: 865-6.
72. Paty DW, Hartung HP, Ebers GC, Soelherg-Sorensen P, Abramsky O, Kesselring J, et al. Management of relapsing-remitting multiple sclerosis: diagnosis and treatment guidelines. Eur Neurol 1999; 6 (Suppl 1): S1-35.
73. Confavreux C, Vukusic S, Moreau T, Adelfme P. Relapses and progression of disability in multiple sclerosis. N Engl J Med 2000; 342: 1430-7.